These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 7517477

  • 1. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
    Moody AP, al-Khaffaf HS, Lehert P, Harris PL, Charlesworth D.
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
    [Abstract] [Full Text] [Related]

  • 2. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
    Kieffer E, Bahnini A, Mouren X, Gamand S.
    Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
    [Abstract] [Full Text] [Related]

  • 3. Naftidrofuryl in intermittent claudication: a retrospective analysis.
    Lehert P, Comte S, Gamand S, Brown TM.
    J Cardiovasc Pharmacol; 1994 Mar; 23 Suppl 3():S48-52. PubMed ID: 7517478
    [Abstract] [Full Text] [Related]

  • 4. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
    Adhoute G, Andreassian B, Boccalon H, Cloarec M, Di Maria G, Lefebvre O, Mondine P, Plagnol P, Pointel JP, Quancard X.
    J Cardiovasc Pharmacol; 1990 Mar; 16 Suppl 3():S75-80. PubMed ID: 1369725
    [Abstract] [Full Text] [Related]

  • 5. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
    D'Hooge D, Lehert P, Clement DL.
    Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
    [Abstract] [Full Text] [Related]

  • 6. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
    Hood SC, Moher D, Barber GG.
    CMAJ; 1996 Oct 15; 155(8):1053-9. PubMed ID: 8873633
    [Abstract] [Full Text] [Related]

  • 7. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
    Nenci GG, Gresele P, Ferrari G, Santoro L, Gianese F, Mesoglycan Intermittent Claudication Group.
    Thromb Haemost; 2001 Nov 15; 86(5):1181-7. PubMed ID: 11816704
    [Abstract] [Full Text] [Related]

  • 8. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program.
    Spengel F, Clément D, Boccalon H, Liard F, Brown T, Lehert P.
    Int Angiol; 2002 Mar 15; 21(1):20-7. PubMed ID: 11941270
    [Abstract] [Full Text] [Related]

  • 9. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation.
    De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, Bucci M, Geroulakos G, Ramaswami G, Vasdekis S, Agus G, Bavera P, Ippolito E.
    Angiology; 2002 Mar 15; 53 Suppl 1():S7-12. PubMed ID: 11865838
    [Abstract] [Full Text] [Related]

  • 10. The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
    Lehert P, Riphagen FE, Gamand S.
    J Cardiovasc Pharmacol; 1990 Mar 15; 16 Suppl 3():S81-6. PubMed ID: 1369727
    [Abstract] [Full Text] [Related]

  • 11. [Padma-28, a herbal preparation, increases walking distance in patients with intermittent claudication].
    Drabaek H, Mehlsen J, Petersen JR, Himmelstrup H, Hansen KF.
    Ugeskr Laeger; 1994 Oct 17; 156(42):6207-9. PubMed ID: 7998359
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial.
    Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Bavera P, Ippolito E.
    Angiology; 2002 Oct 17; 53 Suppl 1():S1-5. PubMed ID: 11865828
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication].
    Boccalon H, Lehert P, Mosnier M.
    Ann Cardiol Angeiol (Paris); 2001 Apr 17; 50(3):175-82. PubMed ID: 12555510
    [Abstract] [Full Text] [Related]

  • 18. The effects of sublingual glyceryl trinitrate on walking distance in patients with intermittent claudication. A randomised, doubled-blind, placebo-controlled, cross-over study.
    Heer R, Walker S, MacSweeney S.
    Curr Med Res Opin; 2001 Apr 17; 17(2):113-5. PubMed ID: 11759179
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
    Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Christopoulos D, Agus G, Bavera P, Mondani P, Ippolito E, Flenda F.
    Minerva Cardioangiol; 2002 Dec 17; 50(6):683-90. PubMed ID: 12473989
    [Abstract] [Full Text] [Related]

  • 20. Ketanserin in intermittent claudication. A double-blind placebo-controlled study.
    Clement DL, Duprez D, Van Wassenhove A, Brusselmans F.
    Int Angiol; 1989 Dec 17; 8(2):92-6. PubMed ID: 2681451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.